Advanced search
Publication Cover
Aging Health Volume 4, 2008 - Issue 3
Journal homepage
77
Views
0
CrossRef citations to date
0
Altmetric
Drug Evaluation

Pramipexole in the Management of Parkinson’s Disease

Heinz Reichmann1 University of Dresden, Chair Department of Neurology, Fetscherstrasse 74, D-01307Dresden, Germany. [email protected]Correspondence[email protected]
View further author information
&
Werner Martin Michael Schüpbach2 Centre d‘Investigation Clinique, Centre Hospitalier Pitié-Salpêtrière, 47 boulevard de l‘Hôpital, 75013Paris, France and, Department of Neurology, Bern University Hospital & University of Bern, Switzerland. [email protected]View further author information
Pages 225-235 | Published online: 02 Jun 2008

Bibliography

  • Hughes AJ , DanielSE, Ben-ShlomoY, Lees AJ: The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain125(Pt 4), 861–870(2002).
  • Doty RL , DeemsDA, StellarS: Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration.Neurology38(8), 1237–1244(1988).
  • Muller A , ReichmannH, LivermoreA, HummelT: Olfactory function in idiopathic Parkinson‘s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de novo IPD patients.J. Neural. Transm.109(5–6), 805–811(2002).
  • Braak H , Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E: Staging of brain pathology related to sporadic Parkinson‘s disease. Neurobiol. Aging24(2), 197–211(2003).
  • Tanner CM : Epidemiological clues to the cause of Parkinson‘s disease. In: Movement Disorders, Volume 3. Marsden CD (Ed.). Butteerworth‘s, London, UK 124–146(1994).
  • Rajput AH , RajputA, RajputM: Handbook of Parkinson‘s Disease. Pahwa R, Lyons KE, Koller WC (Eds). Marcel Dekker, NY, USA 17–42(2003).
  • Kieburtz K , RavinaB: Why hasn‘t neuroprotection worked in Parkinson‘s disease?Nat. Clin. Pract. Neurol.3(5), 240–241(2007).
  • Birkmayer W , HornykiewiczO: The L-3,4-dioxyphenylalanine (Dopa)-effect in Parkinson-akinesia.Wien. Klin. Wochenschr.73787–788(1961).
  • Hornykiewicz O : L-dopa: from a biologically inactive amino acid to a successful therapeutic agent.Amino Acids23(1–3), 65–70(2002).
  • Cotzias GC , PapavasiliouPS, FehlingC, KaufmanB, MenaI: Similarities between neurologic effects of L-dopa and of apomorphine.N. Engl. J. Med.282(1), 31–33(1970).
  • Jenner P , TaylorAR, CampbellDB: Letter: Preliminary investigation of the metabolism of piribedil (ET 495); a new central dopaminergic agonist and potential anti-parkinson agent.J. Pharm. Pharmacol.25(9), 749–750(1973).
  • Calne DB , TeychennePF, ClaveriaLE, EastmanR, GreenacreJK, PetrieA: Bromocriptine in parkinsonism.Br. Med. J.4(5942), 442–444(1974).
  • Antonini A , PoeweW: Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson‘s disease.Lancet Neurol.6(9), 826–829(2007).
  • Junghanns S , FuhrmannJT, SimonisGet al.: Valvular heart disease in Parkinson‘s disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov. Disord.22(2), 234–238(2007).
  • Reichmann H , EhretR, HappeSet al.: Cardiac valvulopathy and dopamine agonists – what‘s new? Akt Neurol.3421–24(2007).
  • Kebabian JW , CalneDB: Multiple receptors for dopamine.Nature277(5692), 93–96(1979).
  • Missale C , NashSR, RobinsonSW, Jaber M, Caron MG: Dopamine receptors: from structure to function. Physiol. Rev.78(1), 189–225(1998).
  • Jaber M , RobinsonSW, MissaleC, Caron MG: Dopamine receptors and brain function. Neuropharmacology35(11), 1503–1519(1996).
  • Gurevich EV , JoyceJN: Distribution of dopamine D3 receptor expressing neurons in the human forebrain: comparison with D2 receptor expressing neurons.Neuropsychopharmacology20(1), 60–80(1999).
  • Mierau J , SchingnitzG: Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist.Eur. J. Pharmacol.215(2–3), 161–170(1992).
  • Mierau J , SchneiderFJ, EnsingerHA, Chio CL, Lajiness ME, Huff RM: Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. Eur. J. Pharmacol.290(1), 29–36(1995).
  • Gerlach M , DoubleK, ArzbergerT, LeblhuberF, TatschnerT, RiedererP: Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum.J. Neural. Transm.110(10), 1119–1127(2003).
  • Gerlach M , ReichmannH, RiedererP: Die Parkinson-Krankheit: Grundlagen, Klinik, Therapie. Springer Verlag, Wien, Germany 93 (2007).
  • Foley P , GerlachM, DoubleKL, Riederer P: Dopamine receptor agonists in the therapy of Parkinson‘s disease. J. Neural. Transm.111(10–11), 1375–1446(2004).
  • Millan MJ , MaiofissL, CussacD, Audinot V, Boutin JA, Newman-Tancredi A: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J. Pharmacol. Exp. Ther.303(2), 791–804(2002).
  • Hubble JP , KollerWC, CutlerNRet al.: Pramipexole in patients with early Parkinson‘s disease. Clin. Neuropharmacol.18(4), 338–347(1995).
  • Wright CE , GraselaTH, PhillipsL: The population pharmacokinetics of pramipexole in Parkinson‘s disease patients.Clin. Pharmacol. Ther. 61182. Abstract PII-170 (1997).
  • Rascol O , GoetzC, KollerW, PoeweW, SampaioC: Treatment interventions for Parkinson‘s disease: an evidence based assessment.Lancet359(9317), 1589–1598(2002).
  • Goetz CG , PoeweW, RascolO, SampaioC: Evidence-based medical review update: pharmacological and surgical treatments of Parkinson‘s disease: 2001 to 2004.Mov. Disord.20(5), 523–539(2005).
  • Horstink M , TolosaE, BonuccelliUet al.: Review of the therapeutic management of Parkinson‘s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson‘s disease. Eur. J. Neurol.13(11), 1186–1202(2006).
  • Horstink M , TolosaE, BonuccelliUet al.: Review of the therapeutic management of Parkinson‘s disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society – European Section. Part I: early (uncomplicated) Parkinson‘s disease. Eur. J. Neurol.13(11), 1170–1185(2006).
  • Shannon KM , BennettJP Jr, Friedman JH: Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson‘s disease. The Pramipexole Study Group. Neurology49(3), 724–728(1997).
  • Parkinson Study Group: Safety and efficacy of pramipexole in early Parkinson disease. A randomized dose-ranging study. JAMA278(2), 125–130(1997).
  • Wong KS , LuCS, ShanDE, YangCC, Tsoi TH, Mok V: Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson‘s disease. J. Neurol. Sci.216(1), 81–87(2003).
  • The Parkinson Study Group: A randomized controlled trial comparing pramipexole with levodopa in early Parkinson‘s disease: design and methods of the CALM-PD Study. Parkinson Study Group. Clin. Neuropharmacol.23(1), 34–44(2000).
  • Parkinson Study Group: Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. JAMA284(15), 1931–1938(2000).
  • Holloway RG , ShoulsonI, FahnSet al.: Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch. Neurol.61(7), 1044–1053(2004).
  • Molho ES , FactorSA, WeinerWJet al.: The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson‘s disease. J. Neural. Transm. Suppl.45225–230(1995).
  • Guttman M : Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson‘s disease. International Pramipexole – Bromocriptine Study Group.Neurology49(4), 1060–1065(1997).
  • Lieberman A , RanhoskyA, KortsD: Clinical evaluation of pramipexole in advanced Parkinson‘s disease: results of a double-blind, placebo-controlled, parallel-group study.Neurology49(1), 162–168(1997).
  • Weiner WJ , FactorSA, JankovicJet al.: The long-term safety and efficacy of pramipexole in advanced Parkinson‘s disease. Parkinsonism Relat. Disord.7(2), 115–120(2001).
  • Wermuth L : A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson‘s disease.Eur. J. Neurol.5(3), 235–242(1998).
  • Pinter MM , PogarellO, OertelWH: Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson‘s disease: a double blind, placebo controlled, randomised, multicentre study.J. Neurol. Neurosurg. Psychiatry66(4), 436–441(1999).
  • Möller JC , OertelWH: Pramipexole in the treatment of advanced Parkinson‘s disease.Eur. J. Neurol.7(Suppl.) 121–125(2000).
  • Pogarell O , GasserT, van Hilten JJ et al.: Pramipexole in patients with Parkinson‘s disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study. J. Neurol. Neurosurg. Psychiatry72(6), 713–720(2002).
  • Mizuno Y , YanagisawaN, KunoSet al.: Randomized, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson‘s disease. Mov. Disord.18(10), 1149–1156(2003).
  • Pinter MM , RutgersAW, HebenstreitE: An open-label, multicentre clinical trial to determine the levodopa dose-sparing capacity of pramipexole in patients with idiopathic Parkinson‘s disease.J. Neural. Transm.107(11), 1307–1323(2000).
  • Rektorova I , RektorI, BaresMet al.: Pramipexole and pergolide in the treatment of depression in Parkinson‘s disease: a national multicentre prospective randomized study. Eur. J. Neurol.10(4), 399–406(2003).
  • Poewe WH , RascolO, QuinnNet al.: Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson‘s disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol.6(6), 513–520(2007).
  • Goetz CG , BlasucciL, StebbinsGT: Switching dopamine agonists in advanced Parkinson‘s disease: is rapid titration preferable to slow?Neurology52(6), 1227–1229(1999).
  • Hanna PA , RatkosL, OndoWG, Jankovic J: Switching from pergolide to pramipexole in patients with Parkinson‘s disease. J. Neural. Transm.108(1), 63–70(2001).
  • Linazasoro G : Conversion from dopamine agonists to pramipexole. An open-label trial in 227 patients with advanced Parkinson‘s disease.J. Neurol.251(3), 335–339(2004).
  • Cummings JL : Depression and Parkinson‘s disease: a review.Am. J. Psychiatry149(4), 443–454(1992).
  • Schrag A , JahanshahiM, QuinnN: What contributes to quality of life in patients with Parkinson‘s disease?J. Neurol. Neurosurg. Psychiatry69(3), 308–312(2000).
  • The Global Parkinson‘s Disease Survey Steering Committee: Factors impacting on quality of life in Parkinson‘s disease: results from an international survey. Mov. Disord.17(1), 60–67(2002).
  • Corrigan MH , DenahanAQ, WrightCE, RagualRJ, EvansDL: Comparison of pramipexole, fluoxetine, and placebo in patients with major depression.Depress Anxiety11(2), 58–65(2000).
  • Sporn J , GhaemiSN, SamburMRet al.: Pramipexole augmentation in the treatment of unipolar and bipolar depression: a retrospective chart review. Ann. Clin. Psychiatry12(3), 137–140(2000).
  • Lattanzi L , Dell‘OssoL, CassanoPet al.: Pramipexole in treatment-resistant depression: a 16-week naturalistic study. Bipolar Disord.4(5), 307–314(2002).
  • Cassano P , LattanziL, SoldaniFet al.: Pramipexole in treatment-resistant depression: an extended follow-up. Depress Anxiety20(3), 131–138(2004).
  • Perugi G , ToniC, RuffoloG, FrareF, AkiskalH: Adjunctive dopamine agonists in treatment-resistant bipolar II depression: an open case series.Pharmacopsychiatry34(4), 137–141(2001).
  • Goldberg JF , BurdickKE, EndickCJ: Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added to mood stabilizers for treatment-resistant bipolar depression.Am. J. Psychiatry161(3), 564–566(2004).
  • Zarate CA , Jr., Payne JL, Singh J et al.: Pramipexole for bipolar II depression: a placebo-controlled proof of concept study. Biol. Psychiatry56(1), 54–60(2004).
  • Aiken CB : Pramipexole in psychiatry: a systematic review of the literature.J. Clin. Psychiatry68(8), 1230–1236(2007).
  • Holman AJ , MyersRR: A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications.Arthritis Rheum.52(8), 2495–2505(2005).
  • Reichmann H , BrechtMH, KosterJ, Kraus PH, Lemke MR: Pramipexole in routine clinical practice: a prospective observational trial in Parkinson‘s disease. CNS Drugs17(13), 965–973(2003).
  • Lemke MR , BrechtHM, KoesterJ, Kraus PH, Reichmann H: Anhedonia, depression, and motor functioning in Parkinson‘s disease during treatment with pramipexole. J. Neuropsychiatry Clin. Neurosci.17(2), 214–220(2005).
  • Lemke MR , BrechtHM, KoesterJ, ReichmannH: Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson‘s disease.J. Neurol. Sci.248(1–2), 266–270(2006).
  • Barone P , ScarzellaL, MarconiRet al.: Pramipexole versus sertraline in the treatment of depression in Parkinson‘s disease: a national multicenter parallel-group randomized study. J. Neurol.253(5), 601–607(2006).
  • Piercey MF , HoffmannWE, SmithMW, HyslopDK: Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.Eur. J. Pharmacol.312(1), 35–44(1996).
  • Rascol O , BrooksDJ, KorczynAD, De DeynPP, ClarkeCE, LangAE: A five-year study of the incidence of dyskinesia in patients with early Parkinson‘s disease who were treated with ropinirole or levodopa. 056 Study Group.N. Engl. J. Med.342(20), 1484–1491(2000).
  • Rinne UK , BraccoF, ChouzaCet al.: Early treatment of Parkinson‘s disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. Drugs55(Suppl.) 123–130(1998).
  • Biglan KM , HollowayRG Jr, McDermott MP, Richard IH: Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. Neurology69(2), 187–195(2007).
  • The Parkinson Study Group. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage. Clin. Neuropharmacol.30(2), 72–85(2007).
  • Kleiner-Fisman G , FismanDN: Risk factors for the development of pedal edema in patients using pramipexole.Arch. Neurol.64(6), 820–824(2007).
  • Voon V , HassanK, ZurowskiMet al.: Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology66(11), 1750–1752(2006).
  • Voon V , HassanK, ZurowskiMet al.: Prevalence of repetitive and reward-seeking behaviors in Parkinson disease. Neurology67(7), 1254–1257(2006).
  • Kvernmo T , HartterS, BurgerE: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists.Clin. Ther.28(8), 1065–1078(2006).
  • Kakimura J , KitamuraY, TakataK, Kohno Y, Nomura Y, Taniguchi T: Release and aggregation of cytochrome C and α-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur. J. Pharmacol.417(1–2), 59–67(2001).
  • Iravani MM , HaddonCO, CooperJM, JennerP, SchapiraAH: Pramipexole protects against MPTP toxicity in non-human primates.J. Neurochem.96(5), 1315–1321(2006).
  • Parkinson Study Group: Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA287(13), 1653–1661(2002).
  • Jennings D , MarekK, TabamoR, SeibylJP, GroupIS: No short-term pharmacologic regulation of dopamine transporter. An investigation of the effects of short-term treatment with pramipexole or levodopa on (123-I)β-CIT and SPECT imaging in early Parkinson disease.Mov. Disord.21(Suppl. 15) P1095 (2006).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.